Mannkind, Game-Chancer in Sachen Diabetik? (Seite 159)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 1
Gesamt: 593.804
Gesamt: 593.804
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,1950
USD
+0,12 %
+0,0050 USD
Letzter Kurs 19:11:23 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 2,2999 | +25,68 | |
| 1,9200 | +23,87 | |
| 6,9300 | +17,46 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6595 | -12,24 | |
| 0,5050 | -15,83 | |
| 3,1100 | -18,10 | |
| 1,9500 | -25,14 | |
| 0,5121 | -30,80 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 59.941.701 von Magnetfeldfredy am 22.02.19 14:17:08Sieht gut aus, dann schaun wir mal--besten Dank fürs einstellen 
Nomura bearish on Xencor in premarket analyst action
Feb. 22, 2019 7:40 AM ET|About: Alexion Pharmaceutical... (ALXN)|By: Douglas W. House, SA News Editor
Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim.
Dermira (NASDAQ
ERM) initiated with Outperform rating and $20 (186% upside) price target at SVB Leerink.
Exelixis (NASDAQ:EXEL) initiated with Market Perform rating and $23 (8% upside) price target at BMO.
Galapagos NV (NASDAQ:GLPG) initiated with Outperform rating and $140 (43% upside) price target at SVB Leerink.
GW Pharmaceuticals (NASDAQ:GWPH) initiated with Buy rating and $178 (24% upside) price target at Guggenheim.
Magellan Health (NASDAQ:MGLN) initiated with Buy rating and $84 (19% upside) at BofA/Merrill Lynch.
MannKind (NASDAQ:MNKD) initiated with Outperform rating and $3 (107% upside) price target at SVB Leerink. Shares up 7% premarket.
Feb. 22, 2019 7:40 AM ET|About: Alexion Pharmaceutical... (ALXN)|By: Douglas W. House, SA News Editor
Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim.
Dermira (NASDAQ
ERM) initiated with Outperform rating and $20 (186% upside) price target at SVB Leerink.Exelixis (NASDAQ:EXEL) initiated with Market Perform rating and $23 (8% upside) price target at BMO.
Galapagos NV (NASDAQ:GLPG) initiated with Outperform rating and $140 (43% upside) price target at SVB Leerink.
GW Pharmaceuticals (NASDAQ:GWPH) initiated with Buy rating and $178 (24% upside) price target at Guggenheim.
Magellan Health (NASDAQ:MGLN) initiated with Buy rating and $84 (19% upside) at BofA/Merrill Lynch.
MannKind (NASDAQ:MNKD) initiated with Outperform rating and $3 (107% upside) price target at SVB Leerink. Shares up 7% premarket.
Wieder sehr gute Daten, besonders die Lunge wird nicht geschädigt, dass müsste doch der Gold Standard beim Meal-Time Insulin werden:
MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
GlobeNewswire•February 20, 2019
WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, 2019 and a poster on Wednesday, February 20, 2019 at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019).
“The data to be presented provide additional insight into the pharmacodynamic effects produced by the ultra-rapid pharmacokinetic profile of inhaled Afrezza insulin compared to those associated with subcutaneous rapid acting insulin,” stated Dr. David Kendall, Chief Medical Officer of MannKind. “By delivering a time-action profile closer to that of physiologic insulin action, post-prandial glucose levels and other markers of glycemic control were significantly improved compared to injected insulin in meal-challenge tests in patients with type 2 diabetes.”
Other data presented at this meeting showed that the pulmonary function of patients with diabetes is more impacted by factors such as high body mass index, elevated HbA1c levels and the time since onset of diabetes than by the effect of inhaled insulin. Kendall added “we believe that these and other recently published data significantly advance our understanding of the treatment opportunity that Afrezza therapy can offer.”
Oral Presentation Highlights
Title: Ultra-rapid profile of insulin human inhalation powder mimics time-action profile of physiologic absorption of glucose from mixed-meal tolerance tests in type 2 diabetes
ATTD 2019 Thursday, February 21st (Hall M4): 17:20-17:30
Presenter: Marshall Grant, Senior Director, Head of Pharmaceutical Research, MannKind Corporation
Description: This analysis was based on a randomized cross-over mixed-meal tolerance test study in type 2 diabetes and conducted to determine how the ultra-rapid PK/PD profile of Afrezza affects various facets of glucose control
Highlights: Compared to subcutaneous rapid-acting insulin, the ultra-rapid PK profile of Afrezza resulted in:
reduced glucagon exposure by 30-35%
reduced C-peptide exposure out to 3 hours
better early post-prandial glucose control
a longer period of tight glucose control with higher doses of Afrezza
earlier reductions in free fatty acids and endogenous glucose production
Poster Presentation Highlights
Title: Diabetes Duration, BMI, and HbA1c Have Greater Effects on Pulmonary Function (PF) Than Inhaled Technosphere® Insulin (Encore, previously presented at EASD)
ATTD 2019 Wednesday, February 20th (poster presentation Friday, February 22nd 10:20-10:25 Exhibition Area)
Presenter: Frank Pompilio, PharmD, VP, Medical Affairs, MannKind Corporation
Description: Data from a pulmonary function (PF) study of patients with type 1 and type 2 diabetes was utilized to compare the effects of diabetes duration, body mass index (BMI), and HbA1c on baseline PF and changes in PF during 24 months of treatment between patients receiving Afrezza and those receiving usual care.
Highlights: The magnitude of Afrezza’s effect on FEV1 was comparable to those normally associated with diabetes-related factors such as high BMI, elevated HbA1c and long-standing diabetes
No effects were clinically significant
Afrezza-related decreases in FEV1 were small, non-progressive and reversible after two years of treatment
About ATTD Annual Meeting
The ATTD is a scientific program that brings leading international experts together to discuss breakthroughs in diabetes treatments, technological innovations and showcase the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and much more.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.
About MannKind
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com
Contact:
MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
GlobeNewswire•February 20, 2019
WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, 2019 and a poster on Wednesday, February 20, 2019 at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019).
“The data to be presented provide additional insight into the pharmacodynamic effects produced by the ultra-rapid pharmacokinetic profile of inhaled Afrezza insulin compared to those associated with subcutaneous rapid acting insulin,” stated Dr. David Kendall, Chief Medical Officer of MannKind. “By delivering a time-action profile closer to that of physiologic insulin action, post-prandial glucose levels and other markers of glycemic control were significantly improved compared to injected insulin in meal-challenge tests in patients with type 2 diabetes.”
Other data presented at this meeting showed that the pulmonary function of patients with diabetes is more impacted by factors such as high body mass index, elevated HbA1c levels and the time since onset of diabetes than by the effect of inhaled insulin. Kendall added “we believe that these and other recently published data significantly advance our understanding of the treatment opportunity that Afrezza therapy can offer.”
Oral Presentation Highlights
Title: Ultra-rapid profile of insulin human inhalation powder mimics time-action profile of physiologic absorption of glucose from mixed-meal tolerance tests in type 2 diabetes
ATTD 2019 Thursday, February 21st (Hall M4): 17:20-17:30
Presenter: Marshall Grant, Senior Director, Head of Pharmaceutical Research, MannKind Corporation
Description: This analysis was based on a randomized cross-over mixed-meal tolerance test study in type 2 diabetes and conducted to determine how the ultra-rapid PK/PD profile of Afrezza affects various facets of glucose control
Highlights: Compared to subcutaneous rapid-acting insulin, the ultra-rapid PK profile of Afrezza resulted in:
reduced glucagon exposure by 30-35%
reduced C-peptide exposure out to 3 hours
better early post-prandial glucose control
a longer period of tight glucose control with higher doses of Afrezza
earlier reductions in free fatty acids and endogenous glucose production
Poster Presentation Highlights
Title: Diabetes Duration, BMI, and HbA1c Have Greater Effects on Pulmonary Function (PF) Than Inhaled Technosphere® Insulin (Encore, previously presented at EASD)
ATTD 2019 Wednesday, February 20th (poster presentation Friday, February 22nd 10:20-10:25 Exhibition Area)
Presenter: Frank Pompilio, PharmD, VP, Medical Affairs, MannKind Corporation
Description: Data from a pulmonary function (PF) study of patients with type 1 and type 2 diabetes was utilized to compare the effects of diabetes duration, body mass index (BMI), and HbA1c on baseline PF and changes in PF during 24 months of treatment between patients receiving Afrezza and those receiving usual care.
Highlights: The magnitude of Afrezza’s effect on FEV1 was comparable to those normally associated with diabetes-related factors such as high BMI, elevated HbA1c and long-standing diabetes
No effects were clinically significant
Afrezza-related decreases in FEV1 were small, non-progressive and reversible after two years of treatment
About ATTD Annual Meeting
The ATTD is a scientific program that brings leading international experts together to discuss breakthroughs in diabetes treatments, technological innovations and showcase the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and much more.
About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.
About MannKind
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
MannKind Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com
Contact:
Antwort auf Beitrag Nr.: 59.877.313 von peppino23 am 14.02.19 19:50:01....hoffen wir und vertrauen darauf,,,,irgendwann muss doch der knoten platzeb
Aktie will nach oben, kann aber nicht richtig durchstarten! Offensichtlicher geht es nicht, wird wieder runtergeprügelt. Aber jetzt ist der Zeitpunkt für nur eine gute Nachricht und die Leerverkäufer verbrennen sich ordentlich die Finger. Ich hoffe, denn dann geht es richtig nach Norden
Trading Spotlight
Nicht jammern, der Kurs steigt doch!
Ende letzten Jahres war er bei 0,85 €!
Das sind fast 50% mehr!
Ende letzten Jahres war er bei 0,85 €!
Das sind fast 50% mehr!
Kleine Gewinne werden hier gnadenlos mitgenommen.
Ja leider. Naja müssen wohl auf den großen Knall warten und der wird kommen. Ja es muss dagegen gehalten werden. Ich würde es mir nicht mehr trauen. Eigentlich können nur gute Nachrichten kommen...….
Ja leider. Naja müssen wohl auf den großen Knall warten und der wird kommen. Ja es muss dagegen gehalten werden. Ich würde es mir nicht mehr trauen. Eigentlich können nur gute Nachrichten kommen...….
wäre ja mal wünschenswert. Ich muss endlich mit dem Ding mal Geld verdienen.
Antwort auf Beitrag Nr.: 59.861.125 von Apollonius am 13.02.19 11:12:22Würde mich nicht wundern, wenn heute die $ 1,50 fallen würde
Der Weg in Richtung 1,80 wäre dann frei
Der Weg in Richtung 1,80 wäre dann frei
Ich halte nichts von den Theorien, das jemand etwas weiß. Die werden nur bei unerklärlichen Sprüngen erwähnt. Ich denke es sind ähnliche Sprünge wie bei dem Absturz. Mit solchen Aktionen verdienen manche eine Menge Geld! Vor den Absturz Short und dann Long. Erst wenn wir wieder bei 1,50 € stehen ist der Kurs wieder normal.
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
